Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. (abre una nueva ventana)

Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, el Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ.

Fuente‎: Cancer 2013;119(21):3784-7.

Indexado en‎: PubMed 23921838

DOI‎: 10.1002/cncr.28253

https://www.ncbi.nlm.nih.gov/pubmed/23921838 (abre una nueva ventana)

Low dose bolus aminocaproic acid: an alternative to platelet transfusion in thrombocytopenia? (abre una nueva ventana)

Chakrabarti S, Varma S, Singh S, Kumari S

Fuente‎: Eur J Haematol 1998;60(5):313-4.

Indexado en‎: PubMed 9654162

DOI‎: 10.1111/j.1600-0609.1998.tb01046.x

https://www.ncbi.nlm.nih.gov/pubmed/9654162 (abre una nueva ventana)

The use of antifibrinolytics in pediatric patients with hypoproliferative thrombocytopenia. (abre una nueva ventana)

Delaney M, Matthews DC, Gernsheimer TB

Fuente‎: Pediatr Blood Cancer 2017;64(12):e26641.

Indexado en‎: PubMed 28544698

DOI‎: 10.1002/pbc.26641

https://www.ncbi.nlm.nih.gov/pubmed/28544698 (abre una nueva ventana)

Preliminary experience with epsilon aminocaproic acid for treatment of intractable upper tract hematuria in children with hematological disorders. (abre una nueva ventana)

Kaye JD, Smith EA, Kirsch AJ, Cerwinka WH, Elmore JM

Fuente‎: J Urol 2010;184(3):1152-7.

Indexado en‎: PubMed 20650477

DOI‎: 10.1016/j.juro.2010.05.020

https://www.ncbi.nlm.nih.gov/pubmed/20650477 (abre una nueva ventana)

A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. (abre una nueva ventana)

Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, Eldor A, Ben-Bassat I.

Fuente‎: Leuk Lymphoma 1995;19(1-2):141-4.

Indexado en‎: PubMed 8574160

DOI‎: 10.3109/10428199509059668

https://www.ncbi.nlm.nih.gov/pubmed/8574160 (abre una nueva ventana)

Pediatric off-label use of recombinant factor VIIa. (abre una nueva ventana)

Alten JA, Benner K, Green K, Toole B, Tofil NM, Winkler MK.

Fuente‎: Pediatrics 2009;123(3):1066-72.

Indexado en‎: PubMed 19255041

DOI‎: 10.1542/peds.2008-1685

https://www.ncbi.nlm.nih.gov/pubmed/19255041 (abre una nueva ventana)

Recombinant activated factor VII usage in life threatening hemorrhage: a pediatric experience. (abre una nueva ventana)

Bhat S, Yadav SP, Anjan M, Dinand V, Sachdeva A.

Fuente‎: Indian J Pediatr 2011;78(8):961-8.

Indexado en‎: PubMed 21328080

DOI‎: 10.1007/s12098-011-0364-6

https://www.ncbi.nlm.nih.gov/pubmed/21328080 (abre una nueva ventana)

Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated Factor VII. (abre una nueva ventana)

Brenner B, Hoffman R, Balashov D, Shutluko E, Čulić SD, Nizamoutdinova E.

Fuente‎: Clin Appl Thromb Hemost 2005;11(4):401-10.

Indexado en‎: PubMed 16244765

https://www.ncbi.nlm.nih.gov/pubmed/16244765 (abre una nueva ventana)

Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label. (abre una nueva ventana)

Croteau SE, Nakar C, Neufeld EJ, Shapiro A, Cooper DL

Fuente‎: Pediatr Blood Cancer 2016;63(10):1822-8.

Indexado en‎: PubMed 27232114

DOI‎: 10.1002/pbc.26082

https://www.ncbi.nlm.nih.gov/pubmed/27232114 (abre una nueva ventana)

Use of recombinant factor VIIa prior to lumbar puncture in pediatric patients with acute leukemia. (abre una nueva ventana)

Das P, Carcao M, Hitzler J

Fuente‎: Pediatr Blood Cancer 2006;47(2):206-9.

Indexado en‎: PubMed 16007583

DOI‎: 10.1002/pbc.20467

https://www.ncbi.nlm.nih.gov/pubmed/16007583 (abre una nueva ventana)

A comprehensive review of rFVIIa use in a tertiary care pediatric center. (abre una nueva ventana)

Heller M, Lau W, Pazmino-Canizares J, Brandão LR, Carcao M

Fuente‎: Pediatr Blood Cancer 2008;50(5):1013-7.

Indexado en‎: PubMed 17960639

DOI‎: 10.1002/pbc.21375

https://www.ncbi.nlm.nih.gov/pubmed/17960639 (abre una nueva ventana)

Recombinant activated factor VII for severe gastrointestinal bleeding after chemotherapy in an infant with acute megakaryoblastic leukemia. (abre una nueva ventana)

Kurekci AE, Atay AA, Okutan V, Yavuz ST, Ozcan O

Fuente‎: Blood Coagul Fibrinolysis 2005;16(2):145-7.

Indexado en‎: PubMed 15741803

DOI‎: 10.1097/01.mbc.0000161569.66764.70

https://www.ncbi.nlm.nih.gov/pubmed/15741803 (abre una nueva ventana)

Off-label use of recombinant factor VIIa in pediatric patients. (abre una nueva ventana)

McQuilten ZK, Barnes C, Zatta A, Phillips LE; Haemostasis Registry Steering Committee

Fuente‎: Pediatrics 2012;129(6):e1533-40.

Indexado en‎: PubMed 22641758

DOI‎: 10.1542/peds.2011-2561

https://www.ncbi.nlm.nih.gov/pubmed/22641758 (abre una nueva ventana)

Dosing, efficacy, and safety of recombinant factor VIIa (rFVIIa) in pediatric versus adult patients: the experience of the Hemostasis and Thrombosis Research Society (HTRS) registry (2004-2008). (abre una nueva ventana)

Neufeld EJ, Saxena K, Kessler CM, Cooper DL; HTRS Investigators

Fuente‎: Pediatr Blood Cancer 2013;60(7):1178-83.

Indexado en‎: PubMed 23335449

DOI‎: 10.1002/pbc.24472

https://www.ncbi.nlm.nih.gov/pubmed/23335449 (abre una nueva ventana)

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII: report on one case and review of other uses in acute leukemias. (abre una nueva ventana)

Pamuk GE, Taşçi M, Oztürk E, Demir M.

Fuente‎: Med Oncol 2010;27(1):16-9.

Indexado en‎: PubMed 19137431

DOI‎: 10.1007/s12032-008-9163-y

https://www.ncbi.nlm.nih.gov/pubmed/19137431 (abre una nueva ventana)

Successful treatment of acute lymphoblastic leukemia with l-asparaginase-induced intracranial hemorrhage to activated recombinant factor VIIa in a child. (abre una nueva ventana)

Ucar C, Caliskan U

Fuente‎: Pediatr Hematol Oncol 2006;23(4):339-45.

Indexado en‎: PubMed 16621776

DOI‎: 10.1080/08880010600631987

https://www.ncbi.nlm.nih.gov/pubmed/16621776 (abre una nueva ventana)

Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder. (abre una nueva ventana)

Yilmaz D, Karapinar B, Balkan C, Akisü M, Kavakli K.

Fuente‎: Pediatr Hematol Oncol 2008;25(4):301-11.

Indexado en‎: PubMed 18484474

DOI‎: 10.1080/08880010802016904

https://www.ncbi.nlm.nih.gov/pubmed/18484474 (abre una nueva ventana)

The use of DDAVP in children with bleeding disorders. (abre una nueva ventana)

Ben-Ami T, Revel-Vilk S

Fuente‎: Pediatr Blood Cancer 2013;60 Suppl 1:S41-3.

Indexado en‎: PubMed 23109357

DOI‎: 10.1002/pbc.24335

https://www.ncbi.nlm.nih.gov/pubmed/23109357 (abre una nueva ventana)

Treatment of refractory thrombocytopenic bleeding with 1-desamino-8-D-arginine vasopressin (desmopressin). (abre una nueva ventana)

Kobrinsky NL, Tulloch H

Fuente‎: J Pediatr 1988;112(6):993-6.

Indexado en‎: PubMed 3373409

DOI‎: 10.1016/s0022-3476(88)80234-8

https://www.ncbi.nlm.nih.gov/pubmed/3373409 (abre una nueva ventana)

The use of Tachosil as hemostatic sealant in nephron sparing surgery for Wilms tumor: preliminary observations. (abre una nueva ventana)

Mele E, Ceccanti S, Schiavetti A, Bosco S, Masselli G, Cozzi DA

Fuente‎: J Pediatr Surg 2013;48(3):689-94.

Indexado en‎: PubMed 23480936

DOI‎: 10.1016/j.jpedsurg.2013.01.019

https://www.ncbi.nlm.nih.gov/pubmed/23480936 (abre una nueva ventana)